With New Cancer Drugs, the Challenge Is Finding Where Cost, Value Meet
(5/15, Alaric Dearment, MedCity News) reports “...In the last two decades, numerous new drugs have come to market and turned some cancers that used to be death sentences into manageable or even curable diseases. But one significant hurdle remains: They're often incredibly expensive. So the question that faces payers, physicians and ultimately patients is how to balance the high cost of new cancer therapies – particularly cutting-edge ones like cell therapies – with the value they add to the healthcare system. That will be the topic of a panel discussion at the upcoming MedCity CONVERGE conference, ‘Value and Cost of Novel Cancer Treatments,’ taking place June 19 in Philadelphia.” Full
Want Better Patient Outcomes? Track Physician Adherence to Evidence-Based Medicine
(5/15, Christopher Cheney, HealthLeaders Media) reports “...LaGrangeville, New York–based Health Quest and Western Connecticut Health Network...have been using EHRs to set alerts, to manage order sets called ‘power plans,’ and to give physicians access to the most recent guidelines, best practices, and journal articles...‘We're finding that our increased compliance scores with evidence-based practice are correlating with improved patient outcomes and financial outcomes, which is encouraging. It gives validity to the initiative,’ says Kelly Philiba, ND, physician informaticist at Health Quest.” Full
Reducing Churn to Increase Value in Health Care: Solutions for Payers, Providers, and Policymakers
(5/15, Niko Lehman-White and Saeed Aminzadeh, The Health Care Blog) comments “...The value-based contracts that have proliferated in this country over the past decade and which now account for about half of the money spent on healthcare allow these wellness investments to make good financial sense in addition to benefiting patient health. However, a phenomenon in health coverage in the US is increasing costs, destabilizing care continuity and holding back the potential of value-based care. It prevents us from making the long-term investments we desperately need.” Full
Finding Clinical Assertions in the World of Real-World Evidence
(5/15, Maggie Lynch, Outsourcing Pharma) reports “...Dan Riskin, founder of Verantos, a digital contract research organization, tells Outsourcing-Pharma that RWE has its own place in the clinical and regulatory world, but it's use still has room for improvement. To Riskin, there is more than one type of RWE and in its variances, there are additional aspects of applications. He said that the most commonly seen type of RWE is one that used to find patterns. However, the use of RWE has greater bandwidth, according to Riskin, and can be used to take the place of control arms in clinical trials, bolster regulatory filings, and give a deeper look into the lives of patients.” Full
Scotland: SMC Follows NICE And Backs Lilly's Verzenios In Advanced Breast Cancer
(5/15, Ian Schofield, Pink Sheet) reports “...The SMC has given the all clear to funding for Lilly's Verzenios for breast cancer, Richter's Reagila for schizophrenia, and MSD's Keytruda for melanoma. However, it rejected Alliance's Xonvea for sickness in pregnancy because the evidence on benefits and cost effectiveness did not stack up.” Paid Subscription Required
Lithuania's New Assessment Procedure for Reimbursable Medicines: Will There Be Any Positive Changes?
(5/15, The Pharma Letter) reports “Lithuanian attorney Ruta Pumputiene provides an Expert View on amendments to the Lithuanian Pharmaceutical Law and the subsequent changes to the reimbursable medicines system...These changes will provide the basis for the introduction of an innovative medicines' evaluation mechanism, the so-called health technology assessment, which puts the focus not only on the price but also on the medicine's value in terms of its price and other direct costs.” Paid Subscription Required
NICE Recommends First Ever Treatment for Children with Rare Muscle-Wasting Condition
(5/15, NICE Press Release) “Children with the rare genetic disorder spinal muscular atrophy (SMA) can now be treated with nusinersen after NICE today recommended it following agreement of a deal between the company, Biogen, and NHS England. Nusinersen (also called Spinraza) is the first treatment that targets the underlying cause of SMA.” Full
Health Technology Assessment and Its Use in Drug Policy in Malaysia
Shafie AA, et al.
May 9, 2019, Value in Health Regional Issues
Leveraging Patient/Community Partnerships to Disseminate Patient Centered Outcomes Research in Geriatrics
Lindquist LA, et al.
May 11, 2019, Geriatrics
Comparative Effectiveness of Antifungal Agents in Patients with Hematopoietic Stem Cell Transplantation: A Systematic Review and Network Meta-Analysis
Su HC, et al.
May 15, 2019, Infection and Drug Resistance